Epizyme, Inc.
EPZMN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Feb 13, 2027
39wMarket Overview
Stock performance and key metrics
EPZM News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Tazemetostat
Diffuse Large B-cell Lymphoma (DLBCL)
Prednisolone
B-cell Lymphomas (Phase 1)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tazemetostat | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
Prednisolone | Phase 2 | B-cell Lymphomas (Phase 1) | - | - |
Diffuse Large B-cell Lymphoma (DLBCL)
1 drug in this indication
B-cell Lymphomas (Phase 1)
1 drug in this indication
Relapsed/Refractory Follicular Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply